Thermo Fisher Scientific Inc. TMO
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Thermo Fisher Scientific Inc. gets an algorithmic score of 57/100. It trades at 679.61 $, with a bullish technical trend (RSI 73.8) and 30.5% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Meaningful dividend (28.00%).
Weaknesses
- Shrinking revenue (-0.3% per year).
Fundamentals
| P/E | 36.62 |
| Forward P/E | 24.67 |
| PEG | 1.98 |
| P/B | 4.77 |
| EV/EBITDA | 24.70 |
| P/S | 5.42 |
| ROE % | 13.51 |
| ROA % | 5.13 |
| Gross margin % | 40.99 |
| Operating margin % | 18.75 |
| Net margin % | 15.04 |
| Revenue growth % (y/y) | 10.50 |
| Earnings growth % (y/y) | 9.40 |
| Revenue CAGR % | -0.27 |
| Earnings CAGR % | -1.19 |
| Debt/Equity % | 80.58 |
| Current ratio | 1.55 |
| FCF yield % | 2.50 |
| Dividend yield % | 28.00 |
| Payout % | 9.69 |
Returns
| 1 month | +9.3 % |
| 3 months | +35.7 % |
| 6 months | +41.8 % |
| YTD | +15.0 % |
| 1 year | +46.9 % |
| 3 years | +36.5 % |
| 5 years | +15.5 % |
Risk
| 1-year volatility | 30.5 % |
| Beta | 0.77 |
| 5-year max drawdown | -41.0 % |
| Sharpe 1A | 1.28 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.